<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1393">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04633915</url>
  </required_header>
  <id_info>
    <org_study_id>COVID</org_study_id>
    <nct_id>NCT04633915</nct_id>
  </id_info>
  <brief_title>Antibody Response in Hemodialysis and Non-dialysis Patients Diagnosed With COVID-19.</brief_title>
  <acronym>COV-HD</acronym>
  <official_title>A Comparison of Antibody Response Against SARS-CoV-2 in Hemodialysis and Non-dialysis Patients Diagnosed With COVID-19.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saint Petersburg State University, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Saint Petersburg State University, Russia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is prospective cohort study aimed to compare antibody response against SARS-CoV-2 in&#xD;
      dialysis patients and non-dialysis-dependent volunteers.&#xD;
&#xD;
      The research hypothesis is that dynamic of IgG antibodies against SARS-CoV-2 will differ in&#xD;
      two groups.&#xD;
&#xD;
      To determine whether there is a statistically significant interaction between factors &quot;group&quot;&#xD;
      and &quot;time&quot; on the titer of IgG antibodies against SARS-CoV-2, a two-way repeated measures&#xD;
      ANOVA will be used.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In both groups level of IgG antibodies against SARS-CoV-2 will be measured at the Day 1 (10&#xD;
      weeks from the date of first symptoms), Weeks 8 and 16 from the Day 1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 26, 2020</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-SARS-COV-2 IgG level</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of people with detectable Anti-SARS-COV-2 IgG in study groups</measure>
    <time_frame>Day 1, weeks 8, 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-SARS-COV-2 IgG level</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Dialysis</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Dialysis</arm_group_label>
    <description>Patients with CKD stage 5, treated with maintenance hemodialysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy</arm_group_label>
    <description>Volunteers who are not dialysis-dependent</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum samples for determination of antibodies&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient â‰¥ 18 years old who were diagnosed with SARS-CoV-2 infection confirmed by PCR or&#xD;
        strongly suspected on computed tomography within 10 weeks prior enrollment.&#xD;
&#xD;
        Main group include patients with chronic kidney disease stage 5, receiving hemodialysis as&#xD;
        a renal replacement therapy.&#xD;
&#xD;
        The another group include volunteers who are not dialysis-dependent.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  SARS-CoV-2 infection within 10 weeks prior enrollment, confirmed by PCR or strongly&#xD;
             suspected on computed tomography&#xD;
&#xD;
          -  Providing informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Saint-Petersburg State University Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>190103</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ekaterina Parshina, MD</last_name>
      <phone>+7(812)676-25-21</phone>
      <email>pannn@yandex.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 15, 2020</study_first_submitted>
  <study_first_submitted_qc>November 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2020</study_first_posted>
  <last_update_submitted>January 18, 2021</last_update_submitted>
  <last_update_submitted_qc>January 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Saint Petersburg State University, Russia</investigator_affiliation>
    <investigator_full_name>Ekaterina Parshina</investigator_full_name>
    <investigator_title>Principal investigator, MD</investigator_title>
  </responsible_party>
  <keyword>antibodies</keyword>
  <keyword>IgG</keyword>
  <keyword>CKD</keyword>
  <keyword>hemodialysis</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

